AbbVie has achieved a robust start to 2026, reporting Q1 revenue of approximately $15 billion, exceeding expectations despite a 40.3% revenue decline from Humira. The company plans significant investments of $1.4 billion in a new manufacturing facility in North Carolina as part of a broader $1.78 billion commitment to infrastructure. Despite a drop in stock value, AbbVie remains optimistic, raising its earnings guidance for the year as it focuses on growth in its neuroscience and immunology product lines.
“AbbVie · is · a global biopharmaceutical company”
“AbbVie · has approximately · 57,000 employees”
“AbbVie · discovers, develops, and commercializes · advanced therapies · that have an impact on people's lives”
“ABBV (Common Stock) · is trading at · Price · $201.55”
“ABBV (Common Stock) · has a change of · Change · -1.16”
“AbbVie · reported · sales · $61.2 billion”
“AbbVie · experienced · sales growth · 8.6%”
“AbbVie · is headquartered in · city · North Chicago, Illinois”
“AbbVie · is a · pharmaceutical firm · true”
“AbbVie · has exposure to · immunology · true”
“AbbVie · has exposure to · oncology · true”
“AbbVie · was spun off from · Abbott · early 2013”